Eli Lilly and Co
LLYHealthcare|Drug Manufacturers - General|USA
$927.06
-8.52 (-0.91%)
DCF (FCF)
$74.80
Tangible Book
$15.77
Graham Number
$92.73
Earnings Power
$55.36
Clinical Trials (513)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05708859 Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT | Type II Diabetes, Atherosclerosis | P4 | Recruiting | 120 | RCT, Double-blind | Tirzepatide, Placebo |
| NCT04372277 Taltz in Combination With Enstilar for Psoriasis | Psoriasis | P4 | Recruiting | 25 | Open-label | Enstilar |
| NCT06864403 Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch | Pouchitis, Pouches, Ileoanal | P4 | Recruiting | 25 | Open-label | Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC) |
| NCT06635057 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan | Type 2 Diabetes | P4 | Active | 130 | Open-label | Tirzepatide |
| NCT04607421 A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | Neoplasms | P3 | Active | 831 | RCT, Open-label | Encorafenib, Cetuximab, Oxaliplatin, Irinotecan, Leucovorin, 5-FU, Capecitabine, Bevacizumab |
| NCT06292013 A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | P3 | Active | 17,300 | RCT, Double-blind | Lepodisiran Sodium, Placebo |
| NCT05556512 A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | Obesity, Overweight | P3 | Active | 15,374 | RCT, Double-blind | Tirzepatide, Placebo |
| NCT06972459 A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | Obesity, Overweight | P3 | Recruiting | 600 | RCT, Double-blind | Orforglipron, Placebo |
| NCT05514054 A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer | Breast Neoplasms | P3 | Active | 8,000 | RCT, Open-label | Imlunestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane |
| NCT06672939 A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities | Obesity, Overweight | P3 | Recruiting | 125 | RCT, Double-blind | Orforglipron, Placebo |
| NCT04819100 A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) | Carcinoma, Non-Small-Cell Lung | P3 | Active | 152 | RCT, Double-blind | Selpercatinib, Placebo |
| NCT03773965 A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis | Juvenile Idiopathic Arthritis | P3 | Recruiting | 190 | Open-label | Baricitinib |
| NCT07232719 A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | Obesity, Overweight | P3 | Recruiting | 250 | RCT, Double-blind | Retatrutide, Placebo |
| NCT07222332 A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) | Diabetes Mellitus, Type 1 | P3 | Recruiting | 300 | RCT, Double-blind | Baricitinib, Placebo |
| NCT03432286 A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine | Episodic Migraine | P3 | Active | 533 | RCT, Double-blind | Galcanezumab, Placebo |
| NCT05509777 A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease | Crohn's Disease | P3 | Recruiting | 90 | Open-label | Mirikizumab |
| NCT07142954 Epidemiology and Biomarker Study in Alzheimer's Disease | Alzheimer Disease | P3 | Recruiting | 3,400 | Open-label | — |
| NCT05508789 A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) | Alzheimer Disease, Dementia | P3 | Recruiting | 1,500 | RCT, Double-blind | Donanemab, Placebo |
| NCT06859268 A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity | Obesity | P3 | Active | 643 | RCT, Double-blind | Retatrutide, Placebo |
| NCT05002127 A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | P2P3 | Active | 127 | RCT, Double-blind | Evorpacept (ALX148), Trastuzumab, Ramucirumab, Paclitaxel |
| NCT07174336 A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | Breast Neoplasms, Neoplasm Metastasis | P3 | Recruiting | 920 | RCT, Double-blind | LY4064809, Placebo, Ribociclib, Palbociclib, Abemaciclib, Anastrozole, Letrozole, Exemestane, Fulvestrant |
| NCT06962280 A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | Type 1 Diabetes, Obesity | P3 | Active | 465 | RCT, Double-blind | Tirzepatide, Placebo |
| NCT07035093 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | Obesity, Overweight | P3 | Recruiting | 586 | RCT, Double-blind | Retatrutide, Placebo |
| NCT04469764 Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer | Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma | P2 | Recruiting | 32 | Open-label | Abemaciclib, Anastrozole, Letrozole |
| NCT06226883 A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease | Inflammatory Bowel Diseases, Crohn's Disease | P2 | Recruiting | 385 | RCT, Double-blind | Placebo, MORF-057 |
| NCT06855212 Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC | Head and Neck Squamous Cell Carcinoma | P2 | Recruiting | 21 | Open-label | Cemiplimab, Cetuximab |
| NCT05821959 Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss | Sensorineural Hearing Loss, Bilateral | P1P2 | Recruiting | 22 | Open-label | — |
| NCT05501704 ETHAN - ET for Male BC | Male Breast Cancer, Hormone Receptor-positive Breast Cancer | P2 | Recruiting | 60 | RCT, Open-label | Tamoxifen, Anastrozole, Degarelix, Abemaciclib |
| NCT06967610 Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). | Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia (SLL) | P2 | Recruiting | 40 | Open-label | Pirtobrutinib, Venetoclax, Obinutuzumab |
| NCT05487599 A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED) | Gaucher Disease, Gaucher Disease, Type 1 | P1P2 | Recruiting | 15 | Open-label | — |
| NCT03891784 Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors | Advanced Digestive System Neuroendocrine Neoplasm, Digestive System Neuroendocrine Tumor | P2 | Active | 20 | Open-label | Abemaciclib |
| NCT06517888 Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma | Vestibular Schwannoma | P1P2 | Recruiting | 27 | Open-label | — |
| NCT06158113 Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study | Lichen Planus, Oral, Lichen Planus, Mucosal | P2 | Active | 10 | Open-label | Baricitinib 4 milligram Oral Tablet |
| NCT02711553 A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer | Biliary Tract Cancer, Metastatic Cancer | P2 | Active | 309 | RCT, Double-blind | Ramucirumab, Merestinib, Cisplatin, Gemcitabine, Placebo Oral, Placebo IV |
| NCT06948786 Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial | Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | P2 | Recruiting | 22 | Open-label | Pirtobrutinib, Mosunetuzumab |
| NCT04127578 Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL) | Parkinson Disease | P1P2 | Active | 32 | Open-label | LY3884961, Methylprednisolone, Sirolimus |
| NCT02678182 Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial | Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Gastro-oesophageal Junction | P2 | Active | 494 | RCT, Open-label | Capecitabine, MEDI4736 (Durvalumab), Trastuzumab, Rucaparib, Ramucirumab |
| NCT07269210 A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia | Severe Hypertriglyceridemia | P2 | Recruiting | 60 | RCT, Double-blind | Solbinsiran, Placebo |
| NCT06390956 Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL) | Marginal Zone Lymphoma | P2 | Recruiting | 23 | Open-label | Pirtobrutinib, Rituximab |
| NCT04145349 CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor | Desmoplastic Small Round Cell Tumor | P1P2 | Active | 30 | RCT, Open-label | Ramucirumab, Cyclophosphamide, Vinorelbine |
| NCT06522386 GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma | Mantle Cell Lymphoma | P2 | Recruiting | 40 | Open-label | Pirtobrutinib, Rituximab, Venetoclax |
| NCT05768139 First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | Breast Cancer, Solid Tumors, Adult | P1P2 | Recruiting | 720 | Open-label | STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane |
| NCT06817356 A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder | Alcohol Use Disorder | P2 | Active | 300 | RCT, Double-blind | Mazdutide, Placebo |
| NCT02452008 Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer | Prostate Cancer | P2 | Active | 60 | RCT, Open-label | Enzalutamide, LY2157299 |
| NCT06916078 A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function | Liver Dysfunction, Healthy | P1 | Recruiting | 33 | Open-label | Lepodisiran |
| NCT05617885 Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer | Metastatic Prostate Cancer, Non-metastatic Prostate Cancer | P1 | Active | 9 | RCT, Open-label | Darolutamide, Abemaciclib, GNRH-A Leuprolide Acetate, GNRH-A Goserelin, Degarelix |
| NCT06238479 A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | Metastatic Solid Tumor, Recurrent Solid Tumor | P1 | Recruiting | 490 | Open-label | LY4101174 |
| NCT06586515 MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors | Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer | P1 | Recruiting | 630 | RCT, Open-label | LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil |
| NCT07426380 A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function | Kidney Disease, Renal Insufficiency Chronic | P1 | Recruiting | 28 | Open-label | LY3841136 |
| NCT06945406 A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | P1 | Recruiting | 124 | RCT, Double-blind | LY4057996 SC, LY4057996 IV, Placebo SC, Placebo IV, Degludec SC, Lispro SC, Degludec IV, Pre-study basal insulin SC |
| NCT07258849 A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis | Healthy, Rheumatoid Arthritis (RA) | P1 | Recruiting | 134 | RCT, Open-label | LY4213663, LY4213663, Placebo, Placebo |
| NCT05307705 A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors | Breast Cancer | P1 | Active | 193 | Open-label | LOXO-783, Fulvestrant, Imlunestrant, Abemaciclib, Anastrozole, Exemestane, or Letrozole, Paclitaxel |
| NCT06297590 A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease | Alzheimer Disease | P1 | Recruiting | 48 | RCT, Double-blind | LY3954068, Placebo, Flortaucipir F18 |
| NCT06977880 A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants | Healthy | P1 | Recruiting | 80 | RCT, Single-blind | LY4292009, Placebo |
| NCT07090785 A Study of LY4088044 in Healthy Participants | Healthy | P1 | Recruiting | 104 | RCT, Double-blind | LY4088044, LY4088044, Placebo, Placebo |
| NCT07439250 A Study of Olomorasib (LY3537982) in Healthy Participants | Healthy | P1 | Recruiting | 15 | Open-label | Olomorasib, Fluconazole |
| NCT06085144 Emgality for Migraine in Breastmilk | Migraine | Recruiting | 30 | — | Galcanezumab | |
| NCT03549416 BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic Dermatitis | Atopic Dermatitis | Recruiting | 1,200 | — | — | |
| NCT01848028 PsoBest - The German Psoriasis Registry | Psoriasis, Psoriatic-arthritis | Recruiting | 3,500 | — | — | |
| NCT06906627 Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD) | Chronic Kidney Disease(CKD), Type 2 DM | N/A | Recruiting | 750 | RCT, Open-label | — |
| NCT02431754 A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS). | Benign Prostatic Hyperplasia | P4 | Completed | 171 | RCT, Double-blind | Tadalafil, Placebo, Alpha1 Blocker |
| NCT00190697 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment | Breast Cancer, Endometrial Cancer | P4 | Completed | 70 | Open-label | arzoxifene |
| NCT00406354 Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany | Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder | P4 | Completed | 181 | RCT, Double-blind | Atomoxetine, Placebo |
| NCT00296699 A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression | Atypical Depression | P4 | Completed | 20 | Open-label | Duloxetine |
| NCT00191828 A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme | Weight Gain | P4 | Completed | 60 | RCT, Open-label | olanzapine |
| NCT06901518 The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous Headaches | Post-Traumatic Headache | P4 | Completed | 25 | Open-label | Galcanezumab-Gnlm |
| NCT00266656 Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome | Turner Syndrome | P4 | Completed | 69 | Open-label | Humatrope |
| NCT00049777 A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated) | Sepsis | P4 | Completed | 2,000 | RCT, Double-blind | Drotrecogin Alfa (Activated), Unfractionated heparin, Low molecular weight heparin |
| NCT07059130 Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis | Crohn Disease (CD), Crohns Disease | P4 | Not Yet Recruiting | 150 | Open-label | Mirikizumab |
| NCT00658931 Cymbalta for Depression as a Complication of Bereavement | Depression, Bereavement | P4 | Unknown | 20 | Open-label | Drug treatment with Cymbalta |
| NCT00181766 Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS) | ADHD NOS | P4 | Completed | 45 | Open-label | Strattera (atomoxetine) |
| NCT00190892 Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania | Bipolar Disorder | P4 | Completed | 120 | RCT, Open-label | olanzapine, carbamazepine |
| NCT00071695 Duloxetine vs. Active Comparator in the Treatment of Patients With Depression | Depression | P4 | Completed | 320 | RCT, Double-blind | Duloxetine Hydrochloride, Venlafaxine Extended Release |
| NCT00191282 Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes | Diabetes Mellitus, Type 2, Acute Myocardial Infarction | P4 | Completed | 1,116 | RCT, Open-label | Insulin lispro, Human insulin isophane suspension (NPH), Insulin glargine, Human insulin isophane suspension, Human insulin 30/70 |
| NCT01709110 VERtebral Fracture Treatment Comparisons in Osteoporotic Women | Postmenopausal Osteoporosis | P4 | Completed | 1,366 | RCT, Double-blind | Teriparatide, Risedronate, Placebo, Calcium, Vitamin D |
| NCT00382135 A Study of Semen Characteristics After 9 Months of Daily Tadalafil 20 mg | Erectile Dysfunction | P4 | Completed | 282 | RCT, Double-blind | tadalafil, placebo |
| NCT00960986 A Duloxetine Dosing Strategy Study in Korean Patients With Major Depressive Disorder | Major Depressive Disorder (MDD) | P4 | Completed | 249 | RCT, Open-label | Duloxetine hydrochloride |
| NCT06009653 Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity | Obesity, Metabolic Disease | P4 | Withdrawn | — | RCT, Double-blind | Placebo, Tirzepatide |
| NCT00485862 Combination Therapy in Patients With Depression | Depressive Symptoms | P4 | Completed | 214 | RCT, Double-blind | Atomoxetine Hydrochloride, Sertraline, Placebo |
| NCT01153425 µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis | Osteoporosis, Osteopenia | P4 | Completed | 33 | RCT, Open-label | Teriparatide, Zoledronic Acid |
| NCT00456885 The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women | Obesity, Impaired Glucose Tolerance | P4 | Completed | 41 | RCT, Double-blind | exenatide, Placebo |
| NCT05080218 COVID-19 VaccinE Response in Rheumatology Patients | Rheumatoid Arthritis, Psoriatic Arthritis | P4 | Completed | 841 | RCT, Open-label | Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab |
| NCT00191178 Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes | Type 2 Diabetes | P4 | Completed | 60 | RCT, Open-label | insulin lispro protamine suspension:insulin lispro rDNA origin low mix, insulin glargine |
| NCT00985712 A Study on the Effect of 2 Pen Devices on HbA1c | Diabetes Mellitus, Type 1 | P4 | Completed | 263 | RCT, Open-label | Insulin Lispro, Huminsulin Regular |
| NCT00259298 Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis | Osteoporosis | P4 | Completed | 12 | Open-label | teriparatide |
| NCT00927186 Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women | Osteoporosis, Post-menopausal | P4 | Completed | 69 | RCT, Double-blind | Teriparatide, Zoledronic Acid |
| NCT00216918 Neuropsychological Functioning in Children With Attention-Deficit/Hyperactivity Disorder. | Attention Deficit Hyperactivity Disorder | P4 | Completed | 40 | Open-label | Atomoxetine Hydrochloride |
| NCT00401258 An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome | Irritable Bowel Syndrome | P4 | Completed | 15 | Open-label | duloxetine |
| NCT00100776 Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder | Schizophrenia, Schizoaffective Disorder | P4 | Completed | 600 | RCT, Double-blind | Olanzapine |
| NCT01430104 A Study of Teriparatide in Japanese Osteoporosis Patients | Osteoporosis | P4 | Completed | 30 | Open-label | Teriparatide, Aspara-CA 600 mg, Alfarol 1.0 µg |
| NCT00131469 Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta | Osteogenesis Imperfecta | P4 | Completed | 79 | RCT, Double-blind | Teriparatide (FORTEO), Placebos |
| NCT01000805 A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms | Major Depressive Disorder | P4 | Completed | 528 | RCT, Double-blind | Duloxetine, Placebo |
| NCT03648554 Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST) | Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis | P4 | Unknown | 93 | RCT, Single-blind | dulaglutide (TRULICITY®) 1.5 mg |
| NCT00035256 Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis | Osteoporosis, Postmenopausal | P4 | Completed | 330 | RCT, Double-blind | teriparatide, raloxifene HCl, placebo |
| NCT01130532 A Study in Erectile Dysfunction | Erectile Dysfunction | P4 | Completed | 623 | RCT, Double-blind | Tadalafil, Placebo |
| NCT00471354 A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine | Attention Deficit Hyperactivity Disorder | P4 | Completed | 228 | Open-label | Atomoxetine |
| NCT00485771 Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression | Bipolar Disorder | P4 | Completed | 403 | RCT, Double-blind | Olanzapine, Fluoxetine, Lamotrigine |
| NCT01558700 Duloxetine in Osteoarthritis (OA) Pain | Osteoarthritis | P4 | Completed | 40 | RCT, Double-blind | Duloxetine, Sugar pill |
| NCT01122264 A Study in Patients With Erectile Dysfunction | Erectile Dysfunction | P4 | Completed | 770 | RCT, Open-label | Tadalafil, Sildenafil Citrate |
| NCT00034580 Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder | Bipolar Disorder | P4 | Completed | 326 | RCT, Double-blind | olanzapine, risperidone |
| NCT04031885 A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer | Metastatic Breast Cancer | P4 | Terminated | 4 | RCT, Open-label | Abemaciclib, Fulvestrant, Standard Chemotherapy |
| NCT00438971 The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder | Panic Disorder | P4 | Completed | 15 | Open-label | Duloxetine |
| NCT04427501 A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness | COVID-19 | P2P3 | Completed | 3,307 | RCT, Double-blind | LY3819253, LY3832479, LY3853113, Placebo |
| NCT01015287 A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction | Acute Coronary Syndromes | P3 | Completed | 4,033 | RCT, Double-blind | Placebo, Prasugrel |
| NCT00830960 A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome | Acute Coronary Syndrome | P3 | Completed | 720 | RCT, Double-blind | Prasugrel, Clopidogrel |
| NCT04497987 A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff | COVID-19, SARS-CoV2 | P3 | Completed | 1,180 | RCT, Double-blind | Bamlanivimab, Placebo, Etesevimab |
| NCT00220571 CARESS in Acute Myocardial Infarction | Myocardial Infarction | P3 | Completed | 600 | RCT, Open-label | — |
| NCT00699998 A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects | Acute Coronary Syndrome | P3 | Completed | 9,326 | RCT, Double-blind | Clopidogrel, Prasugrel, Commercially-available Aspirin |
| NCT02132637 A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes | Type 2 Diabetes Mellitus | P3 | Completed | 68 | RCT, Double-blind | Insulin Peglispro, Insulin Glargine |
| NCT01370499 A Study of LY2216684 in Participants With Major Depression Disorder | Major Depressive Disorder | P3 | Completed | 288 | Open-label | LY2216684, SSRI |
| NCT01205438 A Study of LY2127399 in Participants With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus, Connective Tissue Disease | P3 | Completed | 1,124 | RCT, Double-blind | LY2127399, Placebo every 2 weeks, Placebo every 4 weeks |
| NCT00191321 Teriparatide Use in Hip Replaced Subjects | Osteoporosis | P3 | Completed | 60 | Open-label | Teriparatide |
| NCT02584855 A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis | Psoriatic Arthritis | P3 | Completed | 394 | RCT, Double-blind | Ixekizumab, Placebo |
| NCT00447213 A Study for Patients With Type 1 Diabetes Mellitus | Diabetes Mellitus, Type 1 | P2P3 | Completed | 70 | RCT, Open-label | Insulin glargine, Human Insulin Inhalation Powder, Injectable Insulin |
| NCT00044668 Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination | Diabetes Mellitus, Type 2 | P3 | Completed | 155 | Open-label | AC2993 |
| NCT01621191 An Extension Study of Duloxetine in Fibromyalgia (Extension of F1J-JE-HMGZ, NCT01552057) | Fibromyalgia | P3 | Completed | 149 | Open-label | Duloxetine |
| NCT01900665 Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo | Alzheimer's Disease | P3 | Terminated | 2,129 | RCT, Double-blind | Solanezumab, Placebo |
| NCT05963022 A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO) | Type 2 Diabetes | P3 | Completed | 206 | RCT, Double-blind | Tirzepatide, Placebo |
| NCT00320528 Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) | Attention Deficit Disorder With Hyperactivity | P3 | Completed | 269 | Open-label | atomoxetine |
| NCT03882970 A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes | Type 2 Diabetes Mellitus | P3 | Completed | 1,444 | RCT, Open-label | Tirzepatide, Insulin Degludec |
| NCT01194830 Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study | Diabetes Mellitus, Type 2 | P3 | Completed | 234 | RCT, Double-blind | Linagliptin, Placebo |
| NCT01597245 A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) | Psoriasis | P3 | Completed | 1,224 | RCT, Double-blind | 80 mg ixekizumab Dosing Regimen, 50 mg etanercept, Placebo |
| NCT03057977 EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) | Heart Failure | P3 | Completed | 3,730 | RCT, Double-blind | Empagliflozin, Placebo |
| NCT01885078 An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis | Rheumatoid Arthritis | P3 | Completed | 2,877 | RCT, Double-blind | Baricitinib, Placebo |
| NCT00363376 A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain | Weight Gain | P3 | Completed | 42 | RCT, Double-blind | zonisamide, olanzapine, Zonisamide, Sugar Pill (placebo) |
| NCT00211562 Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids | Schizophrenia | P3 | Terminated | 20 | Open-label | Olanzapine, Omega 3, Vitamin E+C |
| NCT00191100 Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix | Cancer of Cervix | P3 | Completed | 515 | RCT, Open-label | Gemcitabine, Cisplatin |
| NCT00190593 Raloxifene Use for The Heart | Cardiovascular Diseases, Breast Neoplasms | P3 | Completed | 10,000 | RCT, Double-blind | raloxifene, placebo |
| NCT00570011 Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients | Growth Hormone Deficiency | P3 | Completed | 112 | RCT, Open-label | Somatropin, Somatropin |
| NCT01168973 A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy | Non-Small Cell Lung Cancer | P3 | Completed | 1,253 | RCT, Double-blind | Ramucirumab, Placebo (for Ramucirumab), Docetaxel |
| NCT00401973 Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine | Schizophrenia, Schizoaffective Disorders | P3 | Completed | 199 | RCT, Open-label | olanzapine, amantadine, metformin, zonisamide |
| NCT00191529 Growth Hormone Treatment in Short Children Born Small for Gestational Age | Infant, Small for Gestational Age | P3 | Completed | 200 | RCT, Open-label | somatropin |
| NCT00520676 Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | P3 | Completed | 260 | RCT, Open-label | pemetrexed, docetaxel, carboplatin |
| NCT01711359 A Study in Participants With Moderate to Severe Rheumatoid Arthritis | Rheumatoid Arthritis | P3 | Completed | 588 | RCT, Double-blind | Baricitinib, Methotrexate, Baricitinib Placebo, MTX Placebo, Folic Acid |
| NCT02709486 Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee. | Osteoarthritis, Hip, Osteoarthritis, Knee | P3 | Completed | 849 | RCT, Double-blind | Tanezumab, Tanezumab, Placebo |
| NCT00191737 An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder | Attention Deficit Hyperactivity Disorder | P3 | Completed | 147 | Open-label | Atomoxetine |
| NCT00948675 Study of Participants With Advanced Non-Small Cell Lung Cancer | Advanced Non-Small Cell Lung Cancer | P3 | Completed | 361 | RCT, Open-label | Pemetrexed, Carboplatin, Paclitaxel, Bevacizumab |
| NCT05362058 A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time | Diabetes, Type 2 Diabetes | P3 | Completed | 928 | RCT, Open-label | Insulin Efsitora Alfa, Insulin Degludec |
| NCT06047548 A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Overweight, Obesity | P3 | Completed | 441 | RCT, Double-blind | Tirzepatide, Placebo |
| NCT00406926 The Effect of Growth Hormone in Very Young Girls With Turner Syndrome | Turner Syndrome | P3 | Completed | 100 | RCT, Open-label | Somatropin |
| NCT00969618 A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder | Attention Deficit Hyperactivity Disorder | P3 | Completed | 211 | Open-label | Atomoxetine |
| NCT00159952 Effect of Hyperglycemia in PAI-1 Activity and the Relationship With Outcome in Severe Sepsis and Septic Shock | Severe Sepsis, Septic Shock | P2P3 | Completed | 90 | RCT, Single-blind | — |
| NCT00424593 Duloxetine Versus Placebo in Chronic Low Back Pain | Back Pain Without Radiation | P3 | Completed | 236 | RCT, Double-blind | Duloxetine, Placebo |
| NCT00324363 Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin | Type 2 Diabetes Mellitus | P3 | Completed | 466 | RCT, Double-blind | exenatide, Placebo |
| NCT03861039 A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes | Type 2 Diabetes Mellitus | P3 | Completed | 443 | RCT, Open-label | Tirzepatide, Oral antihyperglycemic medication (OAM) |
| NCT05822830 A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities | Obesity, Overweight | P3 | Completed | 751 | RCT, Open-label | Tirzepatide, Semaglutide |
| NCT05463744 A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy | Type 1 Diabetes, Diabetes | P3 | Completed | 692 | RCT, Open-label | Insulin Efsitora Alfa, Insulin Degludec |
| NCT03524092 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | P3 | Completed | 1,177 | RCT, Double-blind | Mirikizumab SC, Mirikizumab IV, Placebo SC |
| NCT02435433 A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein | Hepatocellular Carcinoma | P3 | Completed | 399 | RCT, Double-blind | Ramucirumab, Placebo |
| NCT03421379 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus | Diabetes Mellitus | P3 | Completed | 75 | RCT, Open-label | Glucagon Nasal Powder, Glucagon Hydrochloride Solution |
| NCT02963766 A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes | Type 2 Diabetes | P3 | Completed | 154 | RCT, Double-blind | Dulaglutide, Placebo |
| NCT01558271 A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | P3 | Completed | 492 | RCT, Double-blind | LY2189265, Placebo, Liraglutide |
| NCT00049764 Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis | Sepsis | P3 | Completed | 474 | RCT, Double-blind | Drotrecogin alfa (activated), Placebo |
| NCT00140998 Estrogen Treatment (Oral vs. Patches) in Turner Syndrome | Turner Syndrome, Hypogonadism | P3 | Completed | 16 | RCT, Open-label | 17 beta estradiol |
| NCT00577824 Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) | Type 2 Diabetes | P3 | Completed | 181 | RCT, Double-blind | exenatide, exenatide, placebo |
| NCT00785421 Chemotherapy With or Without Enoxaparin in Pancreatic Cancer | Pancreatic Cancer | P2P3 | Completed | 312 | RCT, Open-label | enoxaparin, chemotherapy with LMWH - enoxaparin, only chemotherapy |
| NCT00408993 Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China | Diabetic Neuropathies | P3 | Completed | 215 | RCT, Double-blind | Duloxetine Hydrochloride, Placebo |
| NCT01140347 A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib | Hepatocellular Carcinoma | P3 | Completed | 565 | RCT, Double-blind | Placebo, Ramucirumab DP (IMC-1121B) |
| NCT00095199 Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer | P3 | Completed | 939 | RCT, Open-label | Pemetrexed, Cetuximab, Docetaxel |
| NCT01454284 A Study in Participants With Type I Diabetes Mellitus | Diabetes Mellitus, Type 1 | P3 | Completed | 1,114 | RCT, Double-blind | Glargine, LY2605541, Insulin Lispro |
| NCT04844918 A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease | Obesity | P3 | Completed | 267 | RCT, Double-blind | Tirzepatide |
| NCT02439320 Lasmiditan Compared to Placebo in the Acute Treatment of Migraine: | Acute Migraine | P3 | Completed | 2,231 | RCT, Double-blind | Lasmiditan 100 mg, Lasmiditan 200 mg, Placebo (matches lasmiditan doses) |
| NCT00122824 Duloxetine Compared With Placebo in Patients With Generalized Anxiety Disorder | Anxiety Disorders | P3 | Completed | 480 | RCT, Double-blind | duloxetine hydrochloride, placebo |
| NCT00018174 Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers | Depression, Smoking | P3 | Completed | 247 | RCT, Double-blind | Fluoxetine, Placebo |
| NCT05931380 A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease | Obesity | P3 | Completed | 238 | RCT, Double-blind | Orforglipron, Placebo |
| NCT01003184 Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes | Type 2 Diabetes Mellitus | P3 | Completed | 222 | RCT, Open-label | exenatide once weekly, insulin detemir |
| NCT00702650 A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations | Hypogonadism | P3 | Completed | 155 | Open-label | Testosterone MD-Lotion |
| NCT00543218 PTH Comparison in Post Menopausal Women | Osteoporosis, Post-Menopausal | P3 | Completed | 63 | RCT, Open-label | teriparatide 20 micrograms/day subcutaneous, calcitonin 100 IU/day subcutaneous |
| NCT00958568 A Study in Relapse Prevention of Treatment-Resistant Depression | Treatment Resistant Depression | P3 | Completed | 892 | RCT, Double-blind | Olanzapine and Fluoxetine combination (OFC), Fluoxetine |
| NCT01170663 A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma | Gastric Cancer | P3 | Completed | 665 | RCT, Double-blind | Ramucirumab (IMC-1211B) DP, Placebo, Paclitaxel |
| NCT00191607 A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. | Genital Neoplasms, Female, Fallopian Tube Neoplasms | P3 | Completed | 162 | RCT, Open-label | Gemcitabine, liposomal doxorubicin |
| NCT00433160 Phase 3 Clinical Trial of Teriparatide in Japan | Osteoporosis | P3 | Completed | 207 | RCT, Double-blind | Teriparatide, Placebo |
| NCT01306214 Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2, Obesity | P3 | Completed | 566 | RCT, Double-blind | Placebo, Placebo, Placebo, Placebo, BI 10773, BI 10773 |
| NCT01127633 Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease | Alzheimer's Disease | P3 | Terminated | 1,457 | RCT, Open-label | Solanezumab, Placebo |
| NCT01422876 Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients | Diabetes Mellitus, Type 2 | P3 | Completed | 1,405 | RCT, Double-blind | high dose FDC, BI 10773 high dose, high dose FDC placebo, low dose FDC placebo, high dose FDC placebo, high dose FDC placebo, low dose FDC placebo, low dose FDC placebo, high dose BI 10773 placebo, low dose FDC, high dose FDC placebo, BI 10773 low dose, high dose BI 10773 placebo, high dose BI 10773 placebo, linagliptin, low dose FDC placebo, linagliptin placebo, BI 10773 low dose placebo, linagliptin placebo, low dose BI 10773 placebo, linagliptin placebo, high dose BI 10773 placebo, BI 10773 low dose placebo, low dose BI 10773 placebo, linagliptin placebo |
| NCT04518410 ACTIV-2: A Study for Outpatients With COVID-19 | Coronavirus, Covid19 | P2P3 | Completed | 4,044 | RCT, Double-blind | bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg |
| NCT01473589 Effect of Teriparatide on Hip Fracture Healing | Femur Neck Fracture | P3 | Completed | 122 | RCT, Double-blind | Teriparatide, Placebo |
| NCT01984606 Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P3 | Withdrawn | — | RCT, Double-blind | Empagliflozin, Placebo, Sitagliptin, Placebo |
| NCT00917384 Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma | Gastric Cancer, Adenocarcinoma | P3 | Completed | 355 | RCT, Double-blind | ramucirumab, Placebo |
| NCT03773978 A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis | Juvenile Idiopathic Arthritis | P3 | Completed | 220 | RCT, Double-blind | Baricitinib, Placebo |
| NCT00191919 A Randomized Double Blind Study Evaluating Duloxetine in Outpatients With MDD and Pain | Depressive Disorder, Major | P3 | Completed | 310 | RCT, Double-blind | Duloxetine Hydrochloride, Placebo |
| NCT03830281 A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy | Type 1 Diabetes Mellitus | P3 | Completed | 471 | RCT, Double-blind | Ultra-Rapid Lispro, Insulin Lispro |
| NCT03338023 A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus | Type 1 Diabetes | P3 | Completed | 272 | RCT, Open-label | LY2963016, Lantus®, Insulin Lispro |
| NCT00381342 Safety and Efficacy of Exenatide as Monotherapy | Type 2 Diabetes Mellitus | P3 | Completed | 233 | RCT, Double-blind | exenatide, exenatide, placebo |
| NCT03730662 A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk | Type 2 Diabetes Mellitus | P3 | Completed | 2,002 | RCT, Open-label | Tirzepatide, Insulin Glargine |
| NCT04421027 A Study of Baricitinib (LY3009104) in Participants With COVID-19 | COVID-19 | P3 | Completed | 1,525 | RCT, Double-blind | Baricitinib, Placebo |
| NCT00255138 Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects | Cancer, Cognitive Late Effects | P3 | Withdrawn | — | RCT, Double-blind | Atomoxetine |
| NCT02402933 Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents | Hypoglycemia, Diabetes Mellitus | P3 | Completed | 26 | Open-label | Nasal Glucagon |
| NCT02314117 A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer | Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | P3 | Completed | 645 | RCT, Double-blind | Ramucirumab, Capecitabine, Cisplatin, Placebo, Fluorouracil |
| NCT03963232 A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine | Episodic Migraine | P3 | Completed | 520 | RCT, Double-blind | Galcanezumab, Placebo |
| NCT01937871 A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED) | Benign Prostate Hyperplasia, Erectile Dysfunction | P3 | Completed | 909 | RCT, Double-blind | 5 mg Tadalafil, Placebo, 0.2 mg Tamsulosin |
| NCT00044395 Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes | Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent | P3 | Completed | 200 | RCT, Double-blind | Ruboxistaurin mesylate |
| NCT00190762 A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma | Mesothelioma | P3 | Completed | 240 | RCT, Open-label | Pemetrexed |
| NCT01719003 Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2, Hyperglycemia | P3 | Completed | 1,413 | RCT, Double-blind | Metformin 500 mg bid, Metformin 1000 mg bid, Empagliflozin low dose qd, Empagliflozin high dose qd, Empagliflozin low dose bid, Metformin 500 mg bid, Empagliflozin high dose bid, Empagliflozin low dose bid, Metformin 1000 mg bid, Metformin 500 mg bid, Metformin 1000 mg bid, Empagliflozin high dose bid, Metformin 1000 mg bid, Empagliflozin high dose bid |
| NCT00332202 PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin | Non Hodgkin Lymphoma | P3 | Completed | 758 | RCT, Double-blind | enzastaurin, placebo |
| NCT01084005 Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P3 | Completed | 241 | RCT, Double-blind | linagliptin, placebo |
| NCT05369403 A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab | Atopic Dermatitis | P3 | Completed | 86 | Open-label | Lebrikizumab |
| NCT04501978 ACTIV-3: Therapeutics for Inpatients With COVID-19 | Covid19 | P3 | Completed | 2,753 | RCT, Double-blind | LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814 |
| NCT00421083 Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury | Erectile Dysfunction, Spinal Cord Injuries | P3 | Completed | 180 | RCT, Double-blind | tadalafil |
| NCT00485459 Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD | Attention Deficit Hyperactivity Disorder | P3 | Completed | 106 | RCT, Double-blind | Atomoxetine Hydrochloride, Placebo |
| NCT00129220 Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder | Bipolar Disorder | P3 | Completed | 224 | RCT, Double-blind | olanzapine, haloperidol, placebo |
| NCT00753896 Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin | Type 2 Diabetes | P3 | Completed | 134 | Open-label | exenatide |
| NCT01676701 Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA) | Rheumatoid Arthritis | P3 | Terminated | 8 | RCT, Open-label | Tabalumab Auto-Injector, Tabalumab Prefilled Syringe |
| NCT00408421 Duloxetine Versus Placebo for Osteoarthritis Knee Pain | Osteoarthritis Knee Pain | P3 | Completed | 231 | RCT, Double-blind | Duloxetine, placebo |
| NCT00547287 Studying the Preference of Tadalafil to Sildenafil in Men With Problems Getting an Erection Across Nations | Impotence | P3 | Completed | 2,760 | Open-label | tadalafil, sildenafil |
| NCT05691712 A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes | Diabetes Type 2, Diabetes Mellitus | P3 | Completed | 257 | RCT, Double-blind | Tirzepatide, Placebo |
| NCT00391209 Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 | P3 | Completed | 379 | RCT, Open-label | simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder, intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder |
| NCT00945945 A Study of Duloxetine in Patients With Osteoarthritis Knee Pain | Osteoarthritis Knee Pain | P3 | Completed | 424 | RCT, Double-blind | Duloxetine (DLX), Placebo (PLA) |
| NCT00434954 Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes | Type 2 Diabetes Mellitus | P3 | Completed | 494 | RCT, Open-label | exenatide twice daily (BID), premixed insulin aspart twice daily (BID) |
| NCT01029886 Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes | Type 2 Diabetes Mellitus | P3 | Completed | 912 | RCT, Open-label | exenatide once weekly, liraglutide |
| NCT03559257 A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine | Migraine | P3 | Completed | 463 | RCT, Double-blind | Galcanezumab, Placebo |
| NCT00965419 A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder | Attention Deficit Hyperactivity Disorder | P2P3 | Terminated | 267 | Open-label | Edivoxetine |
| NCT00190619 Efficacy and Safety of Duloxetine | Urinary Stress Incontinence | P3 | Completed | 100 | RCT, Double-blind | Duloxetine, Placebo |
| NCT00236899 Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC | Metastatic Breast Cancer (MBC) | P3 | Completed | 241 | RCT, Open-label | Gemcitabine, Docetaxel, Paclitaxel |
| NCT00191438 Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents | Breast Neoplasms | P3 | Completed | 300 | RCT, Open-label | gemcitabine, capecitabine, docetaxel |
| NCT02260648 A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia | Hypercholesterolemia | P3 | Terminated | 149 | RCT, Double-blind | Evacetrapib, Ezetimibe, Atorvastatin, Placebo |
| NCT01087502 Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment | Diabetes Mellitus, Type 2 | P3 | Completed | 241 | RCT, Double-blind | Glimepiride, Placebo, Placebo, Placebo, Linagliptin |
| NCT02696785 A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis | Spondyloarthritis | P3 | Completed | 341 | RCT, Double-blind | Ixekizumab, Placebo, Adalimumab |
| NCT00767806 A Study for Patient With Chronic Low Back Pain | Chronic Low Back Pain | P3 | Completed | 401 | RCT, Double-blind | Duloxetine, Placebo |
| NCT00088491 Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia | Schizophrenic Disorders | P3 | Completed | 1,205 | RCT, Double-blind | Intramuscular Olanzapine Depot, Oral Olanzapine |
| NCT02152371 A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes | Diabetes Mellitus, Type 2 | P3 | Completed | 300 | RCT, Double-blind | Dulaglutide, Placebo, Insulin Glargine, Metformin |
| NCT00127634 Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes | Diabetes Mellitus, Type 1 | P3 | Completed | 385 | RCT, Open-label | Human Insulin Inhalation Powder, Injectable Insulin, Insulin Glargine |
| NCT00429858 Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer | Pancreatic Cancer | P2 | Terminated | 21 | Open-label | S-1, gemcitabine hydrochloride |
| NCT04634409 A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness | COVID-19 | P2 | Completed | 1,755 | RCT, Double-blind | Bamlanivimab, Etesevimab, Placebo, VIR-7831, Bebtelovimab |
| NCT00910299 Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI) | Coronary Artery Disease (CAD) | P2 | Terminated | 423 | RCT, Double-blind | Prasugrel, Clopidogrel |
| NCT00320541 A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer | Breast Cancer | P2 | Completed | 187 | RCT, Open-label | gemcitabine, paclitaxel, bevacizumab |
| NCT00190944 Effects of Teriparatide on Distal Radius Fracture Healing | Colles' Fracture | P2 | Completed | 105 | RCT, Double-blind | Teriparatide, placebo |
| NCT04305236 Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer | Breast Neoplasm, Hormone Receptor Positive Breast Carcinoma | P2 | Terminated | 1 | Open-label | Abemaciclib, Fulvestrant |
| NCT01490632 A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis | Psoriasis, Skin Diseases | P2 | Completed | 271 | RCT, Double-blind | Placebo, Baricitinib |
| NCT00055432 Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer | Ovarian Cancer, Peritoneal Cancer | P2 | Terminated | — | Open-label | Gemzar and Alimta |
| NCT04701658 A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19) | COVID-19 | P2 | Completed | 109 | Open-label | Bamlanivimab |
| NCT01900652 A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants | Carcinoma, Non-Small-Cell Lung | P2 | Completed | 111 | RCT, Open-label | Emibetuzumab, Erlotinib |
| NCT04493502 A Study of LY3041658 in Adults With Hidradenitis Suppurativa | Hidradenitis Suppurativa | P2 | Completed | 72 | RCT, Double-blind | Placebo, LY3041658 |
| NCT00326911 Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer | Metastatic Pancreatic Cancer | P2 | Terminated | 61 | RCT, Open-label | cetuximab, bevacizumab, gemcitabine, cetuximab |
| NCT00840034 A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder | Depressive Disorder, Major | P2 | Completed | 227 | RCT, Double-blind | LY2216684, Placebo |
| NCT01473563 A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) | Nonsquamous Non-Small Cell Neoplasm of Lung, Non-Small Cell Lung Cancer Metastatic | P2 | Completed | 52 | Open-label | Pemetrexed |
| NCT02628028 A Study of LY3337641 in Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Terminated | 286 | RCT, Double-blind | LY3337641, Placebo |
| NCT00617734 Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck | Head and Neck Cancer | P2 | Completed | 97 | RCT, Open-label | IMC-A12 (cixutumumab), cetuximab (Erbitux ®) |
| NCT00191490 A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | P2 | Completed | 162 | RCT, Open-label | Gemcitabine, docetaxel, cisplatin |
| NCT06797310 Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Active Hair Shedding: A Prospective Open-Label Study | Alopecia Areata | P2 | Not Yet Recruiting | 30 | Open-label | Baricitinib |
| NCT03485976 Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP) | Pityriasis Rubra Pilaris | P2 | Completed | 12 | Open-label | Ixekizumab |
| NCT03574818 Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001 | Squamous Cell Lung Cancer | P2 | Terminated | 1 | Open-label | Necitumumab-Gemcitabine-Cisplatin |
| NCT00523419 Chemotherapy for Patients With Osteosarcoma | Osteosarcoma | P2 | Completed | 32 | Open-label | Pemetrexed |
| NCT00630149 Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy | Nasopharyngeal Neoplasms | P2 | Completed | 35 | Open-label | Pemetrexed (Alimta) |
| NCT00661492 Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC) | Androgen-independent Prostate Cancer | P2 | Completed | 115 | RCT, Open-label | cetuximab, Mitoxantrone |
| NCT02308020 A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain | Breast Cancer, Non-small Cell Lung Cancer | P2 | Completed | 162 | Open-label | Abemaciclib |
| NCT00003670 Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer | Ovarian Cancer, Primary Peritoneal Cavity Cancer | P2 | Completed | — | — | arzoxifene hydrochloride |
| NCT00128856 Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients | Breast Cancer | P2 | Completed | 46 | Open-label | Gemcitabine, Adriamycine, Paclitaxel |
| NCT00216203 Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer | Non-Small Cell Lung Cancer | P1P2 | Completed | 36 | Open-label | Pemetrexed, Cetuximab |
| NCT01774981 Study of LY3016859 in Participants With Diabetic Nephropathy | Diabetic Nephropathy | P1P2 | Completed | 60 | RCT, Double-blind | Placebo, LY3016859 |
| NCT04145700 CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma | Synovial Sarcoma | P1P2 | Terminated | 23 | RCT, Open-label | Ramucirumab, Gemcitabine, Docetaxel |
| NCT00656084 Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell | Relapsed or Refractory Mantle Cell Lymphoma (MCL) | P2 | Completed | 16 | Open-label | gemcitabine, mitoxantrone, rituximab |
| NCT00356525 Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor | Lung Neoplasms | P2 | Terminated | 41 | RCT, Open-label | pemetrexed, gemcitabine, carboplatin, Pemetrexed |
| NCT00402116 Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients | Glioblastoma, Glioblastoma Multiforme | P1P2 | Completed | 72 | Open-label | enzastaurin, temozolomide |
| NCT02708095 A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | P2 | Completed | 314 | RCT, Double-blind | Baricitinib, Placebo |
| NCT00966875 A Study in Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Completed | 448 | RCT, Double-blind | LY2439821, Placebo |
| NCT00530335 Atomoxetine Phase 2 Study in Japanese Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD) | Attention Deficit Hyperactivity Disorder | P2 | Completed | 45 | Open-label | Atomoxetine |
| NCT03994796 Genetic Testing in Guiding Treatment for Patients With Brain Metastases | CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain | P2 | SUSPENDED | 186 | Open-label | Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib |
| NCT03086369 A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer | Metastatic Pancreatic Cancer | P1P2 | Completed | 184 | RCT, Double-blind | Olaratumab, Nab-paclitaxel, Gemcitabine, Placebo |
| NCT01214603 A Study in Participants With Acute Leukemia | Leukemia | P2 | Completed | 20 | Open-label | LY2090314 |
| NCT00192088 A Study of Pemetrexed Plus Oxaliplatin as First Line Therapy in Advanced Gastric Carcinoma | Advanced Gastric Carcinoma | P2 | Completed | 43 | Open-label | pemetrexed, oxaliplatin |
| NCT01011868 Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P2 | Completed | 494 | RCT, Double-blind | BI 10773 placebo, BI 10773 low dose, BI 10773 high dose, BI 10773 placebo |
| NCT00374868 Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable) | Urologic Neoplasms | P1P2 | Completed | 59 | Open-label | pemetrexed, cisplatin |
| NCT01160744 A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) | Carcinoma, Non-Small-Cell Lung | P2 | Completed | 280 | RCT, Open-label | IMC-1121B (ramucirumab), Pemetrexed, Carboplatin (AUC 6), Cisplatin, Gemcitabine, Carboplatin (AUC 5) |
| NCT01282463 Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma | Carcinoma of Urinary Tract, Urethral Carcinoma | P2 | Completed | 148 | RCT, Open-label | Docetaxel, Ramucirumab DP, Icrucumab |
| NCT01316263 A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors | Gastrointestinal Stromal Tumor (GIST) | P2 | Terminated | 21 | Open-label | Olaratumab |
| NCT00055250 A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer | Pancreatic Cancer | P2 | Completed | 130 | RCT, Double-blind | Gemcitabine, LY293111, placebo |
| NCT01649297 A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy | Diabetes Mellitus, Type 2 | P2 | Completed | 983 | RCT, Double-blind | Placebo, Placebo, Placebo, Placebo, Placebo, empagliflozin (low dose qd), Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Empagliflozin (high dose qd), empagliflozin (high dose bid), Placebo, empagliflozin (low dose bid) |
| NCT01204710 A Study of Olaratumab (IMC-3G3) in Prostate Cancer | Prostate Cancer | P2 | Completed | 123 | RCT, Open-label | Olaratumab, Mitoxantrone, Prednisone |
| NCT00190567 Biomechanical Effects of Duloxetine on Bladder and Sphincter Muscle Function in Women in Pure Genuine Stress Incontinence | Urinary Stress Incontinence | P2 | Completed | 50 | RCT, Double-blind | duloxetine, Placebo |
| NCT05007769 Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC | Non-small Cell Lung Cancer, Non-small Cell Carcinoma | P2 | Withdrawn | — | Open-label | Ramucirumab, Atezolizumab, N-803 |
| NCT00447421 A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy | Small Cell Lung Cancer, Carcinoma, Small Cell | P1P2 | Terminated | 9 | Open-label | pemetrexed, cisplatin |
| NCT06124807 A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight | Obesity, Overweight and Obesity | P2 | Completed | 179 | RCT, Double-blind | LY3305677, Placebo |
| NCT00444678 Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer | Colorectal Cancer, Neoplasm Metastasis | P2 | Completed | 36 | Open-label | Cetuximab, Oxaliplatin, Capecitabine |
| NCT02423343 A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma | Solid Tumor, Non-Small Cell Lung Cancer Recurrent | P1P2 | Completed | 41 | Open-label | Galunisertib, Nivolumab |
| NCT01561430 Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease | Alzheimer's Disease | P1P2 | Terminated | 70 | RCT, Double-blind | LY2886721, Placebo |
| NCT04433585 A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | P2 | Completed | 291 | RCT, Double-blind | LY3471851, Placebo |
| NCT00191984 A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | P2 | Completed | 46 | Open-label | pemetrexed, irinotecan |
| NCT00099333 Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents | Type 2 Diabetes Mellitus | P2 | Completed | 49 | RCT, Open-label | exenatide, Insulin |
| NCT00384774 A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine | Migraine | P2 | Completed | 130 | RCT, Double-blind | Lasmiditan, Placebo |
| NCT03962738 A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine | Migraine | P2 | Completed | 846 | RCT, Double-blind | Lasmiditan, Placebo |
| NCT00535860 Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis | Osteoporosis | P2 | Completed | 104 | RCT, Double-blind | Teriparatide |
| NCT01200290 A Study in Participants With End-Stage Renal Disease | Kidney Failure, Chronic | P2 | Completed | 18 | Open-label | LY2127399 |
| NCT00790790 A Study in the Treatment of Osteoarthritis Knee Pain | Osteoarthritis Knee Pain | P2 | Completed | 147 | RCT, Double-blind | Placebo, LY545694 49 mg, LY545694 105 mg |
| NCT00201760 Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer | Breast Cancer | P2 | Completed | 10 | RCT, Open-label | Gemcitabine, Trastuzumab, Cisplatin |
| NCT02148250 PK/PD Study of U-500 Regular Insulin | Type 2 Diabetes, Insulin Resistance | P2 | Completed | 17 | RCT, Double-blind | U-500 insulin, 100 syringe units, U-500 insulin, 200 syringe units |
| NCT00623974 Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia | Hypocalcemia | P2 | Terminated | 7 | RCT, Open-label | Teriparatide (Forteo), Calcium, Calcitriol |
| NCT07030868 A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes | Obesity, Overweight | P2 | Terminated | 1 | RCT, Double-blind | LY6249492, Placebo |
| NCT00843518 Treatment for Aggression and Agitation in Patients With Alzheimer's Disease | Alzheimer's Disease | P2 | Completed | 132 | RCT, Double-blind | LY451395, Placebo |
| NCT00191022 Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder | Social Phobia | P2 | Completed | 185 | RCT, Double-blind | LY686017, paroxetine, placebo |
| NCT04456686 Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis | Osteoarthritis | P2 | Completed | 117 | RCT, Double-blind | LY3016859, Placebo |
| NCT00402051 Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC) | Non-Small-Cell Lung Cancer | P2 | Completed | 133 | RCT, Open-label | Pemetrexed, Cisplatin, Carboplatin |
| NCT00383266 A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer | Esophageal Neoplasms | P2 | Terminated | 9 | Open-label | Pemetrexed, Carboplatin |
| NCT00169195 Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma | Diffuse Large Cell Lymphoma | P2 | Completed | 49 | Open-label | Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX) |
| NCT00116519 A Study in People With Abnormal Fat Levels in the Blood | Dyslipidemia | P2 | Completed | 300 | RCT, Double-blind | PPAR alpha, placebo |
| NCT02959177 A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine | Migraine | P2 | Completed | 459 | RCT, Double-blind | Galcanezumab, Placebo |
| NCT01936324 A Safety, Tolerability and Preliminary Efficacy Study of DRM01B Topical Gel | Acne Vulgaris | P1P2 | Completed | 114 | RCT, Double-blind | Olumacostat Glasaretil Gel, 7.5% |
| NCT00661427 Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer | Head and Neck, Squamous Cell Cancer | P2 | Completed | 61 | RCT, Open-label | cetuximab, cetuximab |
| NCT00415168 Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer | Gastric Cancer | P2 | Completed | 53 | Open-label | pemetrexed, cisplatin |
| NCT01703091 A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | P2 | Completed | 197 | RCT, Double-blind | Ramucirumab, Placebo, Docetaxel |
| NCT00191789 Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer | Breast Cancer | P2 | Completed | 65 | Open-label | gemcitabine, doxorubicin, cisplatin |
| NCT00804973 Study in Participants With Acute Migraines Headaches | Migraine Headache | P2 | Terminated | 120 | RCT, Double-blind | LY2590443, Placebo injection, Sumatriptan, Placebo capsule |
| NCT00327002 A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism | Metabolic Syndrome X | P2 | Completed | 40 | RCT, Double-blind | LY518674 |
| NCT00191724 Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study | Submassive Pulmonary Embolism | P2 | Completed | 47 | RCT, Double-blind | Drotrecogin Alfa (Activated), Enoxaparin, Placebo, Drotrecogin Alfa (Activated), Drotrecogin Alfa (Activated), Drotrecogin Alfa (Activated) |
| NCT00744991 A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma | Cutaneous T-Cell Lymphoma | P2 | Completed | 25 | Open-label | Enzastaurin |
| NCT00540124 Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men | Benign Prostatic Hyperplasia | P2 | Completed | 151 | RCT, Double-blind | Tadalafil, Placebo, Tamsulosin |
| NCT00133380 A Study in People With High Cholesterol | Hypercholesterolemia | P2 | Completed | 300 | RCT, Double-blind | PPAR alpha, atorvastatin, placebo |
| NCT00254254 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | P2 | Completed | 13 | RCT, Single-blind | Exenatide - Exenatide - Placebo, Exenatide - Placebo - Exenatide, Placebo - Exenatide - Exenatide |
| NCT04534283 A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib. | Cancer, Cancer Metastatic | P2 | Terminated | 16 | Open-label | Abemaciclib, LY3214996 |
| NCT02443337 A Study of LY3023414 and Necitumumab in Squamous Lung Cancer | Non-small Cell Lung Cancer Metastatic | P2 | Terminated | 31 | Open-label | LY3023414, Necitumumab |
| NCT01484431 A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | P1P2 | Completed | 20 | Open-label | Tadalafil- Tablet or Oral suspension |
| NCT00192062 A Trial of Gemcitabine Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer | Breast Cancer | P2 | Completed | 80 | Open-label | gemcitabine, vinorelbine |
| NCT04003896 A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma | Biliary Tract Carcinoma | P2 | Terminated | 4 | Open-label | Abemaciclib |
| NCT00390182 Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC) | Gastrointestinal Neoplasms, Ovarian Neoplasms | P1P2 | Completed | 38 | Open-label | Gemcitabine |
| NCT00450762 Gemcitabine + Carboplatin in Breast Cancer | Breast Cancer | P2 | Completed | — | Open-label | gemcitabine, carboplatin |
| NCT07483073 A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease | Colitis, Ulcerative, Crohn Disease | P2 | Not Yet Recruiting | 60 | RCT, Open-label | Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), LY4395089 |
| NCT01234402 Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients | Breast Cancer | P2 | Completed | 153 | RCT, Open-label | Ramucirumab DP, IMC-18F1, Capecitabine |
| NCT00538681 Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo | Lung Cancer | P2 | Terminated | 35 | RCT, Double-blind | enzastaurin, pemetrexed, cisplatin, placebo |
| NCT00034541 Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | P1P2 | Completed | 32 | Open-label | cetuximab, paclitaxel, carboplatin |
| NCT00491075 Pemetrexed Plus Gemcitabine in Renal Cell Cancer | Renal Cell Carcinoma | P2 | Terminated | 16 | Open-label | Pemetrexed, Gemcitabine |
| NCT01739309 Study of LY2835219 for Mantle Cell Lymphoma | Mantle Cell Lymphoma | P2 | Completed | 28 | Open-label | Abemaciclib |
| NCT05063539 A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease | Alzheimer Disease | P2 | Completed | 327 | RCT, Double-blind | LY3372689, LY3372689, Placebo |
| NCT02624700 2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer | Breast Cancer, Metastatic Breast Cancer | P2 | Terminated | 13 | Open-label | Experimental Arm A: Pemetrexed, Experimental Arm A: Sorafenib, Experimental Arm B: Pemetrexed, Experimental Arm B: Sorafenib |
| NCT00191971 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen | Urologic Neoplasms, Carcinoma, Transitional Cell | P2 | Completed | 40 | Open-label | Gemcitabine |
| NCT00485810 Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With Schizophrenia | Schizophrenia | P1P2 | Completed | 31 | RCT, Open-label | Olanzapine Hydrochloride |
| NCT00784875 An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia | Primary Insomnia, Secondary Insomnia | P2 | Completed | 643 | RCT, Double-blind | LY2624803, LY2624803, Placebo, zolpidem |
| NCT00362102 A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma | Colorectal Carcinoma | P2 | Completed | 38 | Open-label | Cetuximab |
| NCT00226577 Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer. | Lung Cancer | P2 | Completed | 52 | Open-label | Gemcitabine, Pemetrexed |
| NCT00489359 Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer | Ovarian Cancer, Primary Peritoneal Cancer | P1P2 | Completed | 86 | Open-label | Pemetrexed - Phase 1, Carboplatin - Phase 1, Pemetrexed - Phase 2, Carboplatin - Phase 2 |
| NCT00191750 A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned | Carcinoma, Small Cell | P2 | Completed | 80 | RCT, Open-label | Pemetrexed |
| NCT00906282 Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer | Non Small Cell Lung Cancer | P2 | Completed | 46 | Open-label | Pemetrexed, Carboplatin |
| NCT00280150 Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | Lung Cancer | P1P2 | Completed | 46 | Open-label | bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel |
| NCT02549989 Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer | Endometrial Cancer, Recurrent Endometrial Cancer | P2 | Completed | 28 | Open-label | LY3023414 |
| NCT03831191 A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis | P2 | Terminated | 136 | RCT, Double-blind | LY3375880, Placebo |
| NCT01107912 Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease | Coronary Artery Disease | P1 | Completed | 155 | RCT, Double-blind | prasugrel, clopidogrel |
| NCT04611789 A Study of LY3832479 (LY-CoV016) in Healthy Participants 1 | Healthy | P1 | Completed | 18 | RCT, Double-blind | LY3832479, Placebo |
| NCT01107925 Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease | Coronary Artery Disease | P1 | Completed | 72 | RCT, Double-blind | prasugrel, clopidogrel |
| NCT01178099 An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults | Anemia, Sickle Cell | P1 | Completed | 26 | Open-label | Prasugrel |
| NCT01107899 Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes | Acute Coronary Syndromes | P1 | Terminated | 29 | RCT, Open-label | clopidogrel, prasugrel |
| NCT02528396 To Investigate the Efficacy and Safety of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 1 Diabetes Mellitus | Type 1 Diabetes Mellitus | P1 | Completed | 36 | RCT, Double-blind | BioChaperone insulin lispro, Humalog® |
| NCT05313802 A Study of LY3502970 in Healthy Overweight and Obese Participants | Healthy, Obese | P1 | Completed | 72 | RCT, Double-blind | LY3502970 |
| NCT04099277 A Study of LY3435151 in Participants With Solid Tumors | Solid Tumor, Triple-negative Breast Cancer | P1 | Terminated | 2 | Open-label | LY3435151, Pembrolizumab |
| NCT02770521 A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants | Healthy | P1 | Completed | 23 | RCT, Double-blind | Treprostinil, Placebo, LY900014, Insulin Lispro |
| NCT05596747 A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 | P1 | Completed | 31 | RCT, Open-label | LY3209590, Insulin Glargine |
| NCT03188510 A Study of Two Different Formulations of LY3074828 in Healthy Participants | Healthy | P1 | Completed | 54 | RCT, Open-label | LY3074828 |
| NCT01569126 A Study of LY110140 in Healthy Japanese Male Participants | Healthy Volunteer | P1 | Completed | 56 | RCT, Double-blind | LY110140, Placebo |
| NCT01346358 A Study of IMC-CS4 in Subjects With Advanced Solid Tumors | Neoplasms | P1 | Completed | 52 | Open-label | IMC-CS4 |
| NCT02144285 A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis | Kidney Failure, Chronic | P1 | Completed | 64 | RCT, Double-blind | LY3113593, LY3113593, Placebo, Placebo |
| NCT05580250 A Study of LY3526318 in Healthy Male Japanese Participants | Healthy | P1 | Withdrawn | — | RCT, Double-blind | LY3526318, Placebo, Iohexol, Simvastatin, Metformin |
| NCT01577355 A Study of LY2784544 in Healthy Male Subjects | Healthy Male Volunteers | P1 | Completed | 8 | Open-label | — |
| NCT01903083 Chemoimmunotherapy and Radiation in Pancreatic Cancer | Locally Advanced Malignant Neoplasm | P1 | Completed | 10 | Open-label | Tadalafil, Gemcitabine |
| NCT03616977 Study to Compare 2 Formulations of LY900014 in Healthy Participants | Healthy | P1 | Completed | 69 | RCT, Double-blind | LY900014 U-200, LY900014 U-100 |
| NCT05994807 A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants | Healthy Volunteers | P1 | Completed | 33 | Open-label | DC-806, Itraconazole, Carbamazepine |
| NCT06215430 A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants | Healthy | P1 | Completed | 16 | Open-label | Caffeine Tablet, Omeprazole capsule, Warfarin tablet, Pirtobrutinib |
| NCT02759107 A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM) | Healthy, Type 2 Diabetes Mellitus (T2DM) | P1 | Completed | 142 | RCT, Double-blind | Tirzepatide, Placebo, Dulaglutide |
| NCT03929744 A Study of LY3502970 in Healthy Participants | Healthy | P1 | Completed | 133 | RCT, Double-blind | LY3502970, Placebo, Atorvastatin, Simvastatin, Midazolam |
| NCT01903434 A Study of Evacetrapib (LY2484595) in Healthy Participants | Healthy Volunteers | P1 | Completed | 60 | RCT, Open-label | Evacetrapib |
| NCT05778864 A Study of LY3473329 in Participants With Impaired and Normal Renal Function | Renal Insufficiency | P1 | Completed | 47 | Open-label | LY3473329 |
| NCT03611608 A Study of LY3316531 in Healthy Participants | Healthy | P1 | Completed | 16 | RCT, Double-blind | LY3316531, Placebo |
| NCT02265536 A Study of LY3022855 In Participants With Breast or Prostate Cancer | Neoplasms, Neoplasm Metastasis | P1 | Completed | 34 | Open-label | LY3022855 |
| NCT02304419 A Study of Galunisertib on the Immune System in Participants With Cancer | Neoplasm | P1 | Completed | 10 | Open-label | Galunisertib |
| NCT05980416 Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 | Stomach Neoplasm, Gastrointestinal Neoplasms | P1 | Terminated | 88 | Open-label | EO-3021, Ramucirumab (CYRAMZA®), Dostarlimab |
| NCT05959109 A Relative Bioavailability Study of Peresolimab (LY3462817) Formulations in Healthy Participants | Healthy | P1 | Completed | 57 | Open-label | Peresolimab |
| NCT01871493 A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants | Healthy Volunteers | P1 | Completed | 40 | Open-label | LY2605541, Insulin Lispro |
| NCT04230122 A Study of LY3478006 in Healthy Participants | Healthy | P1 | Terminated | 4 | RCT, Double-blind | LY3478006 - IV, LY3478006 - SC, Placebo - IV, Placebo - SC |
| NCT03073213 A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris | Psoriasis | P1 | Completed | 32 | RCT, Open-label | Ixekizumab |
| NCT02919696 A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers | Advanced Cancer, Metastatic Cancer | P1 | Completed | 26 | RCT, Open-label | Abemaciclib |
| NCT02703324 A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps | Diabetes Mellitus, Type 1 | P1 | Completed | 30 | RCT, Double-blind | LY900014, Insulin Lispro |
| NCT01632579 A Single Dose Study of LY3023703 in Healthy Participants | Healthy Volunteers | P1 | Completed | 30 | RCT, Double-blind | LY3023703, Placebo, Celecoxib |
| NCT01286818 A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) | Colorectal Carcinoma | P1 | Completed | 6 | Open-label | Ramucirumab (IMC-1121B), Irinotecan, levofolinate, 5-Fluorouracil (5-FU) |
| NCT01908582 A Study of Evacetrapib and Rifampin in Healthy Participants | Healthy Volunteers | P1 | Completed | 26 | Open-label | Evacetrapib, Rifampin |
| NCT01648764 A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread | Malignant Solid Tumor, Solid Tumor | P1 | Completed | 73 | Open-label | LY2334737 |
| NCT03310411 A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants | Healthy | P1 | Completed | 40 | RCT, Double-blind | Lasmiditan, Sumatriptan, Placebo for Lasmiditan, Placebo for Sumatriptan |
| NCT01275157 Disposition of 14C-LY2452473 Following Oral Administration in Healthy Human Subjects | Healthy Volunteers | P1 | Completed | 6 | Open-label | LY2452473 |
| NCT01784211 A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes | Diabetes Mellitus, Type 1 | P1 | Completed | 76 | RCT, Open-label | LY2605541, Insulin Glargine |
| NCT04172987 A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants | Healthy | P1 | Completed | 40 | Open-label | Tirzepatide, EE/NGM |
| NCT02576951 A Study of Galcanezumab in Healthy Participants | Healthy | P1 | Completed | 178 | RCT, Double-blind | Galcanezumab, Placebo |
| NCT02340104 A Study to Measure Baricitinib (LY3009104) Absorption in Healthy Participants | Healthy Volunteers | P1 | Completed | 8 | Open-label | Baricitinib, [^13C4D3^15N]-baricitinib |
| NCT01775904 A Study of Two Dosage Forms of LY2886721 in Healthy Participants | Healthy Volunteers | P1 | Completed | 26 | RCT, Open-label | LY2886721 in a Capsule, LY2886721 in an orally disintegrating tablet (ODT) |
| NCT02595736 A Study of LY3200327 in Healthy Participants | Healthy | P1 | Completed | 52 | RCT, Double-blind | Placebo (SC), LY3200327 (SC), LY3200327 (IV), Placebo (IV) |
| NCT02951780 A Study of LY3185643 and rGlucagon in Healthy Participants | Healthy | P1 | Completed | 23 | RCT, Double-blind | LY3185643, rGlucagon |
| NCT01354496 A Study of LY2409021 Formulations and the Effect of Food | Healthy Volunteers | P1 | Completed | 35 | RCT, Open-label | LY2409021 Reference Form, LY2409021 Test-Med Formulation (medium particle size), LY2409021 Test-High Formulation (high particle size), LY2409021 Test-Low Formulation (low particle size) |
| NCT03057145 Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors | Solid Tumor | P1 | Completed | 29 | Open-label | Prexasertib, Olaparib |
| NCT01388335 A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin | Solid Tumor, Lymphoma, Malignant | P1 | Completed | 13 | Open-label | warfarin, enzastaurin |
| NCT05630274 A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants | Healthy | P1 | Completed | 32 | RCT, Double-blind | Selpercatinib, Moxifloxacin, Placebo |
| NCT05341089 A Study of Two Different Formulations of LY3502970 in Healthy Participants | Healthy | P1 | Completed | 39 | RCT, Open-label | LY3502970 |
| NCT05042310 A Study of LY3541860 in Healthy Japanese and Non-Japanese Participants | Healthy | P1 | Completed | 94 | RCT, Double-blind | LY3541860, Placebo |
| NCT03977974 A Study of LY3526318 in Healthy Participants | Healthy | P1 | Terminated | 76 | RCT, Double-blind | LY3526318, Placebo |
| NCT02572687 A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | P1 | Completed | 85 | Open-label | Ramucirumab, MEDI4736 |
| NCT02623452 A Study of a New Type of Insulin in Participants With Type 1 Diabetes on Insulin Injection Therapy | Diabetes Mellitus, Type 1 | P1 | Withdrawn | — | RCT, Double-blind | Insulin Lispro |
| NCT02327143 A Study of LY2835219 in Healthy Participants | Healthy Volunteers | P1 | Completed | 11 | Open-label | LY2835219, ¹³C₈-LY2835219 |
| NCT03367390 A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM) | Type1 Diabetes Mellitus | P1 | Completed | 30 | Open-label | Insulin Lispro |
| NCT04515576 A Study of LY3493269 in Participants With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P1 | Completed | 56 | RCT, Double-blind | LY3493269, Dulaglutide, Placebo |
| NCT02588950 A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P1 | Terminated | 11 | RCT, Open-label | U-500R |
| NCT05609825 A Study of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia | Hypertriglyceridemia | P1 | Terminated | 41 | RCT, Double-blind | LY3875383, Placebo |
| NCT06007651 A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD) | Dyslipidemias, Non-Alcoholic Fatty Liver Disease | P1 | Terminated | 49 | RCT, Double-blind | LY3885125, Placebo |
| NCT06165146 A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants | Healthy | P1 | Completed | 16 | Open-label | Repaglinide, Pirtobrutinib |
| NCT03629054 This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills | Healthy | P1 | Completed | 30 | RCT, Open-label | Empagliflozin, Metformin HCl, Linagliptin (fixed dose combination), Empagliflozin, Linagliptin, Metformin HCl |
| NCT03770494 A Study of LY3405105 in Participants With Advanced Cancer | Solid Tumor | P1 | Terminated | 54 | Open-label | LY3405105 |
| NCT06119529 A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis | Healthy, Atopic Dermatitis | P1 | Terminated | 18 | RCT, Double-blind | LY3872386, Prednisone, Placebo |
| NCT06440980 A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight | Healthy, Obese | P1 | Completed | 533 | RCT, Open-label | Orforglipron |
| NCT05110794 A Multiple-Dose Study of LY3502970 in Healthy Participants | Healthy | P1 | Completed | 33 | RCT, Open-label | LY3502970 |
| NCT02326025 A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma | Sarcoma, Soft Tissue | P1 | Completed | 49 | Open-label | Olaratumab, Doxorubicin |
| NCT01263093 A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel | Major Depressive Disorder | P1 | Completed | 47 | RCT, Open-label | Clopidogrel, LY2216684 |
| NCT03363906 A Study of Dulaglutide in Healthy Participants | Healthy | P1 | Completed | 27 | RCT, Open-label | Dulaglutide (Reference), Dulaglutide (Test) |
| NCT02009449 A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | Melanoma, Prostate Cancer | P1 | Completed | 353 | Open-label | Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), gemcitabine/nab-paclitaxel, Capecitabine, Pazopanib, Pembrolizumab, Paclitaxel, nivolumab, Gemcitabine/carboplatin |
| NCT02758171 Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects | Healthy | P1 | Completed | 56 | RCT, Open-label | Empagliflozin, Linagliptin |
| NCT06180967 A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants | Healthy | P1 | Completed | 15 | Open-label | Midazolam Syrup, Midazolam Solution, Pirtobrutinib |
| NCT02568397 A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants | Healthy | P1 | Completed | 60 | Open-label | Lanabecestat, Dabigatran etexilate |
| NCT01849055 A Multiple Dose Study of LY3023703 in Healthy Participants | Healthy Volunteers | P1 | Completed | 48 | RCT, Double-blind | Placebo, LY3023703, Celecoxib |
| NCT04481113 Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer | Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | P1 | Completed | 8 | Open-label | Abemaciclib, Niraparib Tosylate Monohydrate |
| NCT01682135 A Study in Participants With Advanced Solid Tumors | Solid Tumor | P1 | Completed | 28 | Open-label | Ramucirumab |
| NCT07476118 A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity | Obesity, Overweight | P1 | Not Yet Recruiting | 150 | RCT, Double-blind | Brenipatide |
| NCT01965808 A Study of LY2157299 in Healthy Participants | Healthy Volunteers | P1 | Completed | 16 | RCT, Open-label | LY2157299 |
| NCT01870388 A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease | Liver Diseases, Hepatic Insufficiency | P1 | Completed | 16 | Open-label | Baricitinib |
| NCT07446101 A Study of Mirikizumab Solution (LY3074828) in Healthy Participants | Healthy | P1 | Not Yet Recruiting | 450 | RCT, Open-label | Mirikizumab |
| NCT01256567 A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer | Breast Cancer, Metastatic Breast Cancer | P1 | Completed | 7 | Open-label | Ramucirumab, Docetaxel |
| NCT04914546 A Study of LY3819469 in Healthy Participants | Healthy | P1 | Completed | 66 | RCT, Double-blind | LY3819469, Placebo |
| NCT01373931 A Study of LY2216684 in Healthy Females | Depressive Disorder, Major | P1 | Completed | 20 | RCT, Single-blind | LY2216684, Ortho Cyclen, Placebo |
| NCT02161731 Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants | Healthy Volunteers | P1 | Completed | 24 | Open-label | Evacetrapib, Warfarin |
| NCT06173895 A Relative Bioavailability Study of LY3454738 in Healthy Participants | Healthy | P1 | Completed | 30 | RCT, Open-label | LY3454738 |
| NCT04014361 A Study of LY3154885 in Healthy Participants | Healthy | P1 | Terminated | 36 | RCT, Double-blind | LY3154885 - Capsule, Placebo - Capsule, Itraconazole, LY3154885 - Tablet |
| NCT05067270 A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus | Type 1 Diabetes Mellitus | P1 | Completed | 40 | RCT, Double-blind | Sodium Citrate, Treprostinil, Humalog diluent, Magnesium Chloride |
| NCT03928379 A Study of LY3305677 in Participants With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P1 | Completed | 24 | RCT, Double-blind | LY3305677, Placebo |
| NCT04050670 A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes | Healthy | P1 | Completed | 54 | RCT, Open-label | Tirzepatide |
| NCT02575703 A Study of [¹⁴C]-LY3023414 in Healthy Participants | Healthy | P1 | Completed | 8 | Open-label | [¹⁴C]-LY3023414 |
| NCT03343613 A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | Solid Tumor, Non Small Cell Lung Cancer | P1 | Terminated | 60 | Open-label | LY3381916, LY3300054 |
| NCT03076970 Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants | Migraine | P1 | Completed | 42 | RCT, Double-blind | lasmiditan 200 mg, Sumatriptan, matching placebo |
| NCT03848403 Study of Ixekizumab in Healthy Participants | Healthy | P1 | Terminated | 70 | RCT, Single-blind | Ixekizumab |
| NCT02100826 A Study of Cephalexin in Healthy Participants | Healthy Volunteers | P1 | Completed | 28 | RCT, Open-label | Cephalexin |
| NCT01995526 A Study of Insulin Peglispro in Healthy Male Japanese Participants | Healthy Volunteers | P1 | Completed | 11 | Open-label | Insulin Peglispro |
| NCT05338502 Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants | Healthy | P1 | Completed | 20 | Open-label | Selpercatinib, Ranitidine, Omeprazole |
| NCT06503679 A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants | Healthy | P1 | Completed | 49 | Open-label | LY4100511 (DC-853) Dose 1, LY4100511 (DC-853) Dose 2, LY4100511 (DC-853) Dose 3, Midazolam, Repaglinide, Digoxin, Rosuvastatin |
| NCT01606397 A Study of Multiple Increasing Doses of LY2409021 in Participants With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P1 | Completed | 50 | RCT, Double-blind | Placebo, LY2409021 |
| NCT01247350 A Study of LY3009104(Baricitinib) for Healthy Subjects | Healthy Volunteer | P1 | Completed | 34 | RCT, Double-blind | LY3009104, Placebo |
| NCT01430091 A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet | Sickle Cell Disease | P1 | Completed | 18 | RCT, Open-label | Prasugrel (clinical formulation), Prasugrel (Orally Disintegrating Tablet [ODT]) |
| NCT03259490 This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood | Healthy | P1 | Completed | 30 | RCT, Open-label | Empagliflozin/linagliptin/metformin HCl, Empagliflozin, Linagliptin, Metformin HCl |
| NCT01536951 A Study of LY3009104 in Healthy Participants | Healthy Participants | P1 | Completed | 62 | RCT, Double-blind | LY3009104, Placebo, moxifloxacin |
| NCT04923269 A Study of LY3532226 in Healthy Participants | Healthy | P1 | Completed | 41 | RCT, Double-blind | LY3532226, Placebo |
| NCT05444569 A Study of LY3537021 in Healthy Participants | Healthy | P1 | Completed | 47 | RCT, Double-blind | LY3537021, Liraglutide, Placebo |
| NCT01394003 A Study of LY2584702 in Participants With Advanced Cancer | Advanced Cancer | P1 | Terminated | 34 | Open-label | LY2584702 |
| NCT06808802 To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants | Healthy | P1 | Completed | 30 | Open-label | Retatrutide, Metoprolol |
| NCT05810597 A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices | Healthy | P1 | Completed | 65 | RCT, Open-label | Tirzepatide |
| NCT02914379 A Study of LY3337641 in Healthy Male Participants | Healthy | P1 | Completed | 6 | Open-label | [¹⁴C]-LY3337641 |
| NCT01393990 A Study of LY2228820 in Participants With Advanced Cancer | Advanced Cancer | P1 | Completed | 89 | Open-label | LY2228820, Midazolam, Tamoxifen |
| NCT01389765 A Study to Evaluate the Effect of Food on LY2216684 | Depressive Disorder, Major | P1 | Completed | 24 | RCT, Open-label | LY2216684 |
| NCT01253304 A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment | Diabetes Mellitus, Type 2 | P1 | Completed | 26 | Open-label | LY2189265 |
| NCT01459016 A Non-drug Methods Study in Participants With Alzheimer's Disease | Alzheimer's Disease | P1 | Completed | 56 | Open-label | — |
| NCT06194500 A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy Participants | Healthy Male | P1 | Completed | 18 | Open-label | [14C]-LY3549492, LY3549492, [14C]-LY3549492 |
| NCT02659865 A Study of LY3039478 in Healthy Participants | Healthy | P1 | Completed | 29 | RCT, Double-blind | Placebo, LY3039478 Capsule Formulation (Formulation 3), LY3039478 Drug-in Capsule (Reference, Formulation 1), LY3039478 Formulated Capsule (Test, Formulation 3) |
| NCT00287352 Study of Amantadine for Weight Stabilization During Olanzapine Treatment | Psychotic Disorder, Schizophreniform Disorder | P1 | Completed | 40 | RCT, Double-blind | Olanzapine, Amantadine, Olanzapine and placebo |
| NCT04081337 A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide | Obesity | P1 | Completed | 55 | RCT, Double-blind | Tirzepatide, Placebo |
| NCT01524770 A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe | Diabetes Mellitus, Type 2 | P1 | Completed | 50 | RCT, Open-label | Dulaglutide |
| NCT01746745 A Study of LY2940680 in Healthy Participants | Healthy Volunteers | P1 | Completed | 6 | Open-label | [^14C]-LY2940680 |
| NCT01398475 A Relative Bioavailability and Food Effect Study of New Formulations | Chronic Inflammatory Disorder, Arthritis, Rheumatoid | P1 | Completed | 15 | RCT, Open-label | LY3009104 |
| NCT01634165 A Study of LY2963016 in Healthy Participants | Healthy Volunteers | P1 | Completed | 24 | RCT, Double-blind | LY2963016, Lantus |
| NCT04627064 ABEMA Alone or in COMBO With MK-6482 | Clear Cell Renal Cell Carcinoma | P1 | Completed | 11 | Open-label | Abemaciclib, MK-6482 |
| NCT04758234 A Study of LY3549492 in Healthy Participants | Healthy | P1 | Completed | 54 | RCT, Double-blind | LY3549492, Placebo |
| NCT03125239 Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia | Relapsed Adult Acute Myeloid Leukemia, Refractory Adult Acute Myeloid Leukemia | P1 | Completed | 16 | Open-label | Merestinib, LY2874455 |
| NCT06342596 A Study of Carbon-14-Labelled [14C] LY3473329 in Healthy Male Participants | Healthy | P1 | Completed | 16 | Open-label | [14C]-LY3473329, [14C]-LY3473329, LY3473329 |
| NCT02660502 An Euglycemic Clamp Trial to Evaluate Pharmacokinetics of Single Doses of BioChaperone Insulin Lispro in Healthy Japanese Subjects | Healthy | P1 | Completed | 15 | RCT, Double-blind | Biochaperone insulin lispro 0.1 U/kg, Biochaperone insulin lispro 0.2 U/kg, Biochaperone insulin lispro 0.4 U/kg, Humalog® |
| NCT01750853 A Study of LY3045697 in Healthy Participants | Healthy Volunteers | P1 | Completed | 27 | RCT, Double-blind | LY3045697, Placebo |
| NCT00207077 Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors | Neoplasms | P1 | Completed | 33 | Open-label | Cetuximab + Erlotinib |
| NCT02529553 A Study of LY3076226 in Participants With Advanced or Metastatic Cancer | Advanced Cancer, Metastatic Cancer | P1 | Completed | 25 | Open-label | LY3076226 |
| NCT05727072 A Study of LY3848575 in Healthy Participants | Healthy | P1 | Completed | 64 | RCT, Double-blind | LY3848575, LY3848575, Placebo, Placebo |
| NCT03933943 A Study of LY3361237 in Participants With Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic | P1 | Completed | 28 | RCT, Double-blind | LY3361237, Placebo |
| NCT03726125 A Study of LY3374849 in Healthy Participants | Healthy | P1 | Completed | 89 | RCT, Double-blind | LY3374849 - SC, Insulin Degludec - SC, LY3374849 - IV, Insulin Degludec - IV |
| NCT03023826 A Study of LY3202626 in Healthy Participants | Healthy | P1 | Completed | 26 | RCT, Open-label | LY3202626 (R-Fasting), LY3202626 (T1-Fasting), LY3202626 (T1-Fed) |
| NCT01807026 A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease | Alzheimer Disease, Healthy Volunteers | P1 | Completed | 36 | RCT, Double-blind | LY2886721, Placebo |
| NCT02778126 A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer | Advanced Cancer | P1 | Completed | 6 | Open-label | [¹⁴C]Prexasertib, Prexasertib |
| NCT03997981 Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY) | Chemotherapy-induced Peripheral Neuropathy | Unknown | 200 | — | — | |
| NCT02065765 International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer | Metastatic Gastric Cancer, Metastatic Adenocarcinoma of the Gastroesophageal Junction | APPROVED_FOR_MARKETING | — | — | Ramucirumab | |
| NCT01490372 Gestational Diabetes Mellitus and Cardiometabolic Syndrome in Offspring | Gestational Diabetes Mellitus | Completed | 41 | — | — | |
| NCT04030728 Implementing Patients´ Competence in Oral Breast Cancer Therapy | Metastatic Breast Cancer, Advanced Breast Cancer | Unknown | 212 | — | — | |
| NCT01074151 The Cymbalta Pregnancy Registry | Pregnancy | Completed | 144 | — | duloxetine | |
| NCT00540241 Performance Status During Treatment With Pemetrexed in Patients With NSCLC | Non Small Cell Lung Cancer | Completed | 542 | — | Pemetrexed | |
| NCT03153410 Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas | Pancreatic Cancer | Early P1 | Completed | 11 | Open-label | Cyclophosphamide, GVAX Pancreas Vaccine (GVAX), Pembrolizumab, IMC-CS4 |
| NCT00400166 Recovery Guide Intervention for Recurrent Psychiatric Hospitalization | Schizophrenia, Schizoaffective Disorder | N/A | Completed | 71 | RCT, Open-label | — |
| NCT04667182 A Study of Glucose Control in Participants With Type 1 and Type 2 Diabetes | Type 1 Diabetes, Type 2 Diabetes | Withdrawn | — | — | — | |
| NCT03743285 A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus (T1D) | Type 1 Diabetes Mellitus | N/A | Completed | 10 | Open-label | Insulin Lispro |
| NCT00885807 A Prospective Chart Review to Validate the WFIRS (Weiss Functional Impairment Rating Scale) | Attention-Deficit/Hyperactivity Disorder | Completed | 220 | — | — | |
| NCT00149591 The Viability-Guided Angioplasty After Acute Myocardial Infarction-Trial (The VIAMI-Trial) | Myocardial Infarction, Coronary Artery Disease | N/A | Unknown | 300 | RCT, Open-label | — |
| NCT04623138 A Virtual Prospective Study Exploring Activity Trackers and COVID-19 Infections | Covid19, SARS-CoV Infection | Completed | 847 | — | — | |
| NCT00561509 Multi-Country Observational Study to Collect the Frequency of Sexual Dysfunction With Antidepressant Treatment, Either With SSRIs or Duals at 8 Weeks and 6 Months | Major Depressive Disorder | Completed | 1,626 | — | SSRIs, Dual antidepressants | |
| NCT01936376 A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers | Head and Neck Cancer | Unknown | 150 | — | — | |
| NCT01077323 A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents | Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies) | Completed | 363,766 | — | exenatide, Other antidiabetic therapies | |
| NCT01055808 Observational Study in Japanese Type 2 Diabetes Patients | Diabetes Mellitus, Type 2 | Completed | 677 | — | Insulins | |
| NCT01662817 Major Depressive Disorder (MDD) | Depression | Completed | 525 | — | — | |
| NCT01028352 Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain | Breast Cancer | N/A | Completed | 35 | Open-label | Duloxetine |
| NCT04681768 Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients | Breast Cancer/ Metastatic Breast Cancer | Completed | 95 | — | Abemaciclib | |
| NCT05588622 Meru Health Program for Cancer Patients With Depression and Anxiety | Depression, Anxiety | N/A | Completed | 22 | Open-label | — |
| NCT00538122 Changes in Heart Rhythms Associated With Antipsychotic Drug Treatment | Schizophrenia, Schizoaffective Disorder | Completed | 12 | — | — | |
| NCT01454973 Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects | Type 2 Diabetes | Completed | 25 | — | — | |
| NCT00169702 The Effect of a Weight Management Program During Treatment With Olanzapine | Schizophrenia | N/A | Completed | 100 | RCT, Open-label | — |
| NCT00136929 Senior PAMI: Primary Angioplasty Versus Thrombolytic Therapy for Acute Myocardial Infarction in the Elderly | Myocardial Infarction | N/A | Unknown | 530 | RCT, Open-label | Thrombolytic therapy |
| NCT01088503 Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome | Acute Coronary Syndrome | Completed | 12,227 | — | ADP receptor inhibitors | |
| NCT02792725 Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer | Metastatic Breast Cancer | APPROVED_FOR_MARKETING | — | — | Abemaciclib | |
| NCT02197078 Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin | Diabetes Mellitus, Type 2 | Completed | 189,426 | — | — | |
| NCT00953862 Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility | Attention Deficit Hyperactivity Disorder | N/A | Completed | 18 | Open-label | Atomoxetine |
| NCT01351246 Guided Self-Help for Parents of Children With Attention-Deficit/Hyperactivity Disorder (ADHD) | Attention-Deficit/Hyperactivity Disorder | N/A | Completed | 300 | Open-label | — |
| NCT05692869 A Study of Continuous Blood Pressure Monitoring in Healthy Participants | Healthy | N/A | Completed | 24 | RCT, Open-label | Propranolol, Pseudoephedrine |
| NCT03554434 An Expanded Access Program for AM0010 (Pegilodecakin) | Melanoma, Prostate Cancer | NO_LONGER_AVAILABLE | — | — | AM0010 | |
| NCT03338803 Real World Glycemic Effectiveness of Linagliptin | Diabetes Mellitus, Type 2 | Completed | 11,001 | — | Linagliptin | |
| NCT00512070 Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine | Schizophrenia, Schizoaffective Disorder | N/A | Completed | 40 | RCT, Double-blind | olanzapine and melatonin |
| NCT01724580 Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes | Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE), Juvenile Dermatomyositis (JDM) | APPROVED_FOR_MARKETING | — | — | Baricitinib | |
| NCT01363284 Pretreatment Identification of Duloxetine Success in Neuropathic Pain Patients | Diabetes, Painful Neuropathy | N/A | Completed | 51 | Open-label | Duloxetine |
| NCT03652272 Development and Evaluation of an Electronic Health Record-based Medication Complete Communication (EMC2) Strategy | Medication Adherence | N/A | Completed | 301 | RCT, Open-label | — |
| NCT01400971 An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes | Diabetes Mellitus, Type 2 | Completed | 4,299 | — | — | |
| NCT00933439 Assessment of Cognitive Functioning Before and After Treatment With Duloxetine | Major Depressive Disorder | N/A | Completed | 30 | Open-label | Duloxetine |
| NCT06696456 Long Term Follow-up Study of AAVAnc80-hOTOF Gene Therapy | Otoferlin Gene-mediated Hearing Loss | By Invite | 30 | — | — | |
| NCT01056549 Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans | Hyperlipidemia | N/A | Completed | 15 | RCT, Single-blind | exenatide |
| NCT03761797 A Long-term Study on the Side Effects of TRADIANCE in Japanese Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | Completed | 1,164 | — | TRADIANCE® Combination Tablets AP, TRADIANCE® Combination Tablets BP | |
| NCT03936660 A 12 Month Site Randomized Trial in Adults With Type 2 Diabetes Mellitus and History of Cardiovascular Disease | Diabetes Mellitus, Type 2, Cardiovascular Diseases | N/A | Completed | 1,049 | RCT, Open-label | — |